Current radiomic research in prostate cancer has primarily targeted the prediction of well-established biomarkers such as TP53 and Ki-67, in addition to conventional clinical endpoints like biochemical recurrence (BCR) and extracapsular extension (EPE), which have been extensively investigated (20, 21). This evidence concerns the gene TP53 and Familial prostate cancer.